Takeda Pharmaceutical Co ADR [NYSE: TAK] loss -0.20% or -0.03 points to close at $14.72 with a heavy trading volume of 3598547 shares.
It opened the trading session at $14.71, the shares rose to $14.745 and dropped to $14.625, the range by which the price of stock traded the whole day. The daily chart for TAK points out that the company has recorded 13.32% gains over the past six months.
If we look at the average trading volume of 2.17M shares, TAK reached to a volume of 3598547 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Takeda Pharmaceutical Co ADR [TAK]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for TAK shares is $17.08 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on TAK stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Morgan Stanley have made an estimate for Takeda Pharmaceutical Co ADR shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on April 02, 2025. The new note on the price target was released on March 16, 2023, representing the official price target for Takeda Pharmaceutical Co ADR stock. Previously, the target price had yet another raise from $21 to $24, while Cowen kept a Outperform rating on TAK stock.
The Price to Book ratio for the last quarter was 1.00, with the Price to Cash per share for the same quarter was set at 0.82. Price to Free Cash Flow for TAK in the course of the last twelve months was 9.30 with Quick ratio for the last quarter at 0.52.
Trading performance analysis for TAK stock
Takeda Pharmaceutical Co ADR [TAK] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -2.71. With this latest performance, TAK shares dropped by -3.16% in over the last four-week period, additionally plugging by 13.32% over the last 6 months – not to mention a rise of 11.18% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TAK stock in for the last two-week period is set at 44.00, with the RSI for the last a single of trading hit 0.25, and the three-weeks RSI is set at 0.24 for Takeda Pharmaceutical Co ADR [TAK]. The present Moving Average for the last 50 days of trading for this stock 14.83, while it was recorded at 14.81 for the last single week of trading, and 14.22 for the last 200 days.
Takeda Pharmaceutical Co ADR [TAK]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Takeda Pharmaceutical Co ADR [TAK] shares currently have an operating margin of 13.02% and a Gross Margin at 53.09%. Takeda Pharmaceutical Co ADR’s Net Margin is presently recorded at 2.35%.
Return on Equity for this stock inclined to 0.73%, with Return on Assets sitting at 0.73%. When it comes to the capital structure of this company, Takeda Pharmaceutical Co ADR [TAK] has a Total Debt to Total Equity ratio set at 0.73.
Reflecting on the efficiency of the workforce at the company, Takeda Pharmaceutical Co ADR [TAK] managed to generate an average of $14904.44 per employee.Takeda Pharmaceutical Co ADR’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.52 and a Current Ratio set at 1.01.
Takeda Pharmaceutical Co ADR [TAK]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for TAK. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Takeda Pharmaceutical Co ADR go to 47.03%.
An analysis of Institutional ownership at Takeda Pharmaceutical Co ADR [TAK]
There are presently around $2.30%, or 2.30% of TAK stock, in the hands of institutional investors. The top three institutional holders of TAK stocks are: CAPITAL RESEARCH GLOBAL INVESTORS with ownership of 13.13 million shares, which is approximately 0.8367%. MONDRIAN INVESTMENT PARTNERS LTD, holding 7.74 million shares of the stock with an approximate value of $$108.34 million in TAK stocks shares; and MONDRIAN INVESTMENT PARTNERS LTD, currently with $$64.53 million in TAK stock with ownership which is approximately 0.3138%.
